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license (http://creative(SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer’s dis-
ease (AD).
Methods: One hundred twenty-four subjects with possible mild AD and with neuroimaging evi-
dence of cerebrovascular disease were randomized to placebo or 250-mg rilapladib once daily, for
24 weeks, in addition to stable background acetylcholinesterase inhibitor and/or memantine. The
study assessed the safety and tolerability of rilapladib and its effects on cognition, mechanistic,
and disease-related biomarkers. Although the overall intent behind the study was to take a broad
exploratory view of the data, two primary end points of interest (cerebrospinal fluid [CSF] amyloid
beta peptide 1–42 [Ab1–42] and CogState executive function/working memory [EF/WM] composite
score at week 24) were prespecified in the analysis plan for inferential statistical analysis.
Results: Rilapladib was well tolerated with no significant safety concerns. A significant difference
from placebo was observed for rilapladib on change from baseline in EF/WM (effect size, 0.45;
P 5 .026). There was no significant difference between groups on the change from baseline in
CSFAb1–42 (P5 .133). Preliminary evidence of effects was detected on other mechanistic (albumin
quotient) and disease-related biomarkers (tau/P-tau and neurofilament light chain).
Conclusion: These data provide initial evidence supporting Lp-PLA2 inhibition as a novel treatment
for dementia.
Clinical Trial Registration: Clinicaltrials.gov identifier: NCT01428453.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Rilapladib (SB659032) is a potent and selective inhibitor
of the enzyme lipoprotein-associated phospholipase A2 (Lp-
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commons.org/licenses/by-nc-nd/4.0/).phages, T lymphocytes, and mast cells and circulates in
plasma as a complex with low-density lipoprotein (LDL)
and, to a lesser extent, high-density lipoprotein [1]. A range
of studies demonstrate that inhibition of Lp-PLA2 can
reduce peripheral measures of inflammation in nonclinical
[2] and clinical studies [3–5]. Based on nonclinical data,
rilapladib is not believed to be brain penetrant and has
been evaluated previously in subjects with stable
atherosclerosis [6].
Lp-PLA2 has substrate specificity toward oxidized phos-
pholipids, in particular, those containing a polar fatty acid
moiety that are generated during the oxidation of LDLimer’s Association. This is an open access article under the CC BY-NC-ND
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oxidized phosphatidylcholine in tissue, generating proin-
flammatory lysophosphatidylcholine (lysoPC) and oxidized
nonesterified fatty acids. LysoPC has also been demon-
strated to be a mediator of inflammatory stress on brain
microvascular endothelial cells [7] and to increase the
permeability of endothelial cells [8]. Literature supports
that oxLDL can be detected in the central nervous system
(CNS) after blood-brain barrier (BBB) disruption [9].
In a diabetic mellitus (DM) and hypercholesterolaemic
(HC) pig model, treatment with darapladib (another Lp-
PLA2 inhibitor) numerically reduced the extent of immu-
noglobulin G brain parenchyma penetration suggesting a
reduction in BBB leakage and significantly lowered
the total amount of brain amyloid beta peptide 1–42
(Ab1–42) deposition compared with untreated DM/HC
pigs [10]. Both findings are relevant and potentially
linked, through brain Ab efflux mechanisms at the BBB,
to the pathogenesis and progression of Alzheimer’s dis-
ease (AD) [11,12].
Age-related cerebrovascular dysfunction, and associated
cerebrovascular disease (CVD), plays an important role in
the initiation and progression of AD [13–15]. Cerebral
small vessel disease (SVD) is a CVD subtype that is
associated with a high proportion of AD cases [16–18].
The associated pathologic changes in the parenchymal
small arteries and arterioles (e.g., arteriolosclerotic
changes such as fibrinoid necrosis, lipohylinosis,
microatheroma, and microaneurysms) extend to the
endothelial barriers of the small vessels and capillaries
(i.e., the BBB) resulting in permeability changes and
extravasation of plasma components into the vessel walls
and brain parenchyma [19]. Postmortem analyses of AD
brain tissue have demonstrated changes to the microvascula-
ture through the presence of extravasated serum proteins,
such as albumin and immunoglobulin [20–23], as well as
white matter lesions and the widespread deposition of
cerebral amyloid angiopathy, with associated microbleeds;
all of which may contribute to decline in vascular integrity
and function [19]. These observations, together with the
findings from the nonclinical models, informed on the
choice of AD subjects with neuroimaging evidence of
CVD (e.g., white matter lesions and/or lacunes, typical of
SVD) in the present study.
In summary, it is hypothesized that rilapladib will periph-
erally reduce the production of proinflammatory and toxic
mediators, thereby restoring BBB integrity and reducing
its permeability. Resultant, or downstream, effects may
include reduced levels of neuroinflammation/toxicity and re-
ductions in CNS Ab, either through a reduction in influx or a
restoration of efflux mechanisms.
The present study was designed to investigate the extent
to which the mechanisms observed in preclinical models
are present in subjects with AD and CVD and whether any
downstream impact on neurodegenerative biomarkers or
cognition could be detected over a 24-week treatment period.2. Methods
2.1. Study design
This exploratory study was a randomized, double-blind,
placebo-controlled, parallel group, repeat dose study to eval-
uate the effect of rilapladib on biomarkers related to the
pathogenesis and progression of AD and cognitive function.
Subjects were randomized to either 250 mg of rilapladib or
placebo once daily for 24 weeks in addition to their stable
background therapy (i.e., acetylcholinesterase inhibitor
[AChEI] and/or memantine). Study duration was 30 weeks
comprising 4-week screening, 24-week treatment period,
and 2-week follow-up. The study was conducted at 24 sites
in Germany, Spain, Italy, Sweden, Bulgaria, and Canada.
The study was conducted in accordance with the Interna-
tional Conference on Harmonization Good Clinical Practice
guidelines and the ethical principles that are outlined in the
Declaration of Helsinki 2008. The protocol was reviewed
and approved by ethics committees or institutional review
boards at each institution.2.2. Subjects
Eligible subjects were 50–80 years inclusive and met
National Institute of Neurological and Communicative
Diseases and Stroke/Alzheimer’s Disease and Related
Disorders Association (NINCDS-ADRDA) criteria for
possible AD [24]. Subjects had radiological (magnetic
resonance imaging [MRI] or computed tomography
[CT]) evidence of significant CVD, assessed within the
last 12 months, by meeting at least one of the criteria in
the following:
MRI evidence: White matter lesions: extending caps,
irregular halo, diffusely confluent hyperintensities, or
extensive white matter changes.
CT evidence: Extensive periventricular and deep white
matter lesions: patchy or diffuse symmetrical areas of
low attenuation (intermediate density between normal
white matter and cerebrospinal fluid [CSF]), with ill-
defined margins extending to the centrum semiovale,
and at least one lacunar infarct.
MRI or CT evidence: Lacunar cases: multiple lacunes
(e.g., .5) in the deep gray matter.
Subjects were required to have a Mini-Mental Status
Examination score of 20–26 at screening, a Clinical
Dementia Rating of 0.5 or 1.0, and a documented history
of 6-month AChEI therapy, with two months at a stable
dose.
Exclusion criteria included significant psychiatric illness;
history/evidence of another cause of dementia; history of
seizures; abnormal findings that would preclude participa-
tion; treatment with monoamine oxidase inhibitors, conven-
tional antipsychotics, an investigational drug or treatment
with a potential for interaction with rilapladib. See
Supplementary Materials for further details.
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CSF was collected at baseline and week 24 (or early
withdrawal) for the assessment of Ab1–42 (primary end
point of interest), Ab1–40, total tau (T-tau), 181 phosphory-
lated tau (P-tau), Lp-PLA2 activity, and as an exploratory
marker of axonal degeneration and white matter damage,
neurofilament light chain (NF-L). Albumin quotient
(AlbQ) was also determined as a marker of BBB perme-
ability. Plasma samples were collected at baseline, week
1, week 12, and week 24 for the assessment of Ab1–40,
Ab1–42, and Lp-PLA2 activity. Pharmacokinetics (PKs) of
rilapladib were assessed throughout the study from base-
line to week 24. Further details of assays used to measure
these end points are provided in the Supplementary
Materials.
Cognitive assessment was performed at screening,
baseline, week 12, and week 24 (or early withdrawal)
using a battery of computerized (CogState [25]) as well
as pen and paper neuropsychological assessments, with
executive function/working memory composite score
(EF/WM) as the primary end point of interest. The indi-
vidual tests were selected on the basis of being relatively
free of floor and ceiling effects and their ability to probe
cognitive functions that were likely to demonstrate
decline over 24 weeks in the selected population. The in-
dividual tests and composite scores are described in the
following and in more detail in the Supplementary
Materials.
EF/WM composite: Controlled Oral Word Association
Test, category naming, one back, Trails B, and Go-NoGo.
Attention composite: Identification (a choice reaction
time task) and Trails A.
Episodic memory composite: International Shopping List
Task (ISLT) immediate recall, ISLT delayed recall. Note:
the reporting and analysis plan prespecified a change to
the protocol before unbinding that the episodic memory
composite would only include immediate recall.
Overall composite: all nine subtests.
Safety was assessed throughout the study through
collection of adverse events (AEs), assessment of vital
signs, electrocardiograms, and routine laboratory assess-
ments. In addition, eye examinations (all sites) and elec-
tron microscopy of peripheral blood lymphocytes (in
sites with appropriate facilities) were performed at
screening and week 24 to identify any signs of potential
phospholipidosis.2.4. Randomization and masking
After the run-in period, subjects were randomized in
random permuted blocks of four in a 1:1 ratio to double-
blind treatment with rilapladib of 250 mg or matching pla-
cebo which were provided by GlaxoSmithKline (GSK) as
tablets to be taken once daily after breakfast. The randomi-zation schedule was generated by GSK and implemented us-
ing an interactive voice-response system.With the exception
of two subjects for whom the investigator was unblinded (but
not the sponsor) after a code break, all investigator and
sponsor staff remained blinded to treatment until the data-
base was finalized.2.5. Statistical analysis
Although the overall intent behind the study was to take
a broad exploratory view of the data, two primary end
points of interest were prespecified in the analysis plan
for inferential statistical analysis: end of study/week 24
treatment differences between placebo and rilapladib of
250 mg for the ITT population for CSF Ab1–42 and Cog-
State EF/WM. Assuming a post randomization dropout
rate of 15%, approximately 120 subjects were randomized
to ensure a total of 102 evaluable subjects (51 per group). A
sample size of 51 evaluable subjects per arm allowed a dif-
ference of 70 pg/mL in CSF Ab1–42 between placebo and
rilapladib to be detected with 80% power at a 5% (two
sided) significance level assuming an underlying standard
deviation (SD) of 120.
Three populations were defined for efficacy and safety
analyses: safety (subjects randomized who took at least
one dose of study medication), intent-to treat (ITT; subjects
in the safety population who also had at least one post-
baseline efficacy assessment), and per protocol (PP; subjects
in the ITT population who were not major protocol devia-
tors).
Changes from baseline in CSF parameters were
analyzed using an analysis of covariance, adjusting for
baseline CSF parameter, age, and treatment. Change
from baseline in plasma biomarker parameters and Cog-
State end points were analyzed using a mixed model for
repeated measures, assuming an unstructured covariance
matrix, with the following terms included in the model:
treatment, visit, baseline, treatment by visit, and baseline
by visit.
Statistical significance was interpreted using a two-sided
test at the 5% significance level for the two primary compar-
isons of interest only. No adjustments were made for multi-
plicity of these two coprimary end points. CSF Ab1–42 and
CogState EF/WM were also analyzed using the PP
population.
Results for the analysis of the cognitive end points are
presented as differences in standardized scores (Z scores,
using the mean and SD for the ITT population at baseline)
and effect sizes (treatment difference divided by the standard
error).
Results of primary and some secondary end points are
also presented as posterior probabilities (using a noninfor-
mative prior) for the treatment differences/effect sizes being
above relevant thresholds. See Supplementary Materials for
more details.
Safety data were summarized using descriptive statistics.
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3.1. Patient disposition and demographics
Of the 170 subjects screened for the study, 124 were ran-
domized to treatment with rilapladib or placebo. Early with-
drawal rates were 9/61 subjects (15%) for rilapladib and 6/62
subjects (10%) for placebo. The most common reasons for
withdrawal were AEs (seven subjects [11%] for rilapladib
and two subjects [3%] for placebo) and withdrawn consent
(one subject [2%] for rilapladib and three subjects [5%]
for placebo). Most subjects (93%) in the ITT population
were compliant with treatment.
Demographic and baseline characteristics were similar
across treatment groups (Table 1). All subjects were Cauca-
sian. Most subjects were receiving treatment with an AChEI
with only 12%–13% receiving memantine (Supplementary
Table 1). Examination of baseline CSF profiles of Ab1–42,
tau, and P-tau indicated that approximately 50%–60% of
subjects met the biomarker thresholds for amyloid positivity
and tau levels indicative of AD (Table 1).3.2. PKs and pharmacodynamics
Rilapladib plasma concentrations were within the range
of observation from previous studies [6]. The mean plasma
exposure to SB-664601, one of the major metabolites of
rilapladib, was about 16% of rilapladib.
Target engagement in the plasma was confirmed by
approximately 80% reduction in plasma Lp-PLA2 activity
in the rilapladib group. See Supplementary Table 2 for
further details.
CSF Lp-PLA2 activity was an exploratory measure. Mean
change from baseline at the end of study was20.464 mmol/
min/L in the rilapladib group and 0.026 mmol/min/L in theScreene
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AE: n=2
Protocol DeviaƟon: n=1
Lost to Follow-Up: n=0
Withdrew Consent: n=3
Fig. 1. Subject disposition (safety population). *One subject was randomized in er
treatment group) were randomized and received treatment but withdrew before an
ulation. Abbreviations: AE, adverse event; ITT, intent-to-treat.placebo group, although the data were variable (SD of
5.4263 and 7.2657 for rilapladib and placebo, respectively).
See Supplementary Table 3 for further details.3.3. Efficacy assessments3.3.1. Ab biomarkers
No statistically significant differences were observed for
the change in baseline at week 24 for CSFAb1–42 (P5 .133;
ITT Population, Table 2). PP analysis of CSF Ab1–42 was
consistent with the ITTanalysis, as was a sensitivity analysis
excluding subjects who provided CSF at the early with-
drawal visit or follow-up visit (See Supplementary Table 4).
Based on model checking a number of outliers for CSF
Ab1–40 and Ab1–42 were identified. A sensitivity analysis
excluding these outliers from the ITT population was also
conducted and found to reduce the observed differences be-
tween treatments for both CSF Ab1–42 and Ab1–40 but still
supported the overall interpretation of the ITT analysis
(Supplementary Table 4).
Changes in plasma Abwere small with no differences de-
tected between treatment groups (Table 2).
3.3.2. Albumin quotient
AlbQ was assessed as a mechanistic biomarker of BBB
integrity. Bayesian posterior probability that there was a
true treatment difference in favor of rilapladib for AlbQ,
given the observed data, was approximately 83%. See
Table 2.
3.3.3. Other disease-related biomarkers
T-tau and P-tau were assessed as markers of neurode-
generation and Alzheimer-specific neurodegeneration,d
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Fig. 2. Time profile of executive function/working memory composite
score (adjusted mean change from baseline in Z score 6 95% confidence
intervals [MMRManalysis]). Abbreviation:MMRM,mixedmodel repeated
measures.
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ter damage. Bayesian posterior probabilities that there
was a true treatment difference in favor of rilapladib,
given the observed data, were approximately 90% for
T-tau and P-tau and approximately 80% for NF-L. See
Table 2.
3.3.4. Cognition
Inferential testing on the EF/WM composite score
showed that the treatment difference at week 24 was
statistically significant (P 5 .026). Consistent findings
were observed for the overall composite score with both
end points showing an effect size of .0.4 and a Bayesian
posterior probability of .98% that given the observed
data, the true effect size was .0. Effect sizes for attention
and episodic memory were smaller (Table 3).
The time profile for the EF/WM composite is shown in
Fig. 2. The profile for other composite scores was
similar.
PP analysis of CogState EF/WM was consistent with
the ITT analysis. A number of ad hoc sensitivity analyses
were performed on the cognitive data to explore the
impact of missing data; these analyses supported the inter-
pretation of the ITT analysis (see Supplementary Table 5
for further details). In addition to the treatment by base-
line covariate interaction testing performed for the twoTable 1
Populations and demographic and baseline characteristics (ITT population)
Population/Characteristic
Randomized population, N
Safety population, N
ITT population, N
PP population, N
Demographics and baseline characteristics of ITT population
Gender, % male:female
Age, y
BMI, kg/m2
Median time since first diagnosis, y (range)
MMSE
CDR sum of boxes
CDR global score, % 0.5:1.0
CSF Ab1–42 ,600 ng/L (%)
CSF T-tau .400 ng/L (%)
CSF P-tau .70 ng/L (%)
CSF Ab1–42 ,600 ng/L and CSF T-tau .400 ng/L or CSF P-tau .70 ng/L (%
White matter lesions* (%)
Multiple (.5) lacunes in the deep gray matter (%)
Both white matter lesions and multiple (.5) lacunes in the deep gray matter (%
Hachinski scorey
Abbreviations: ITT, intent-to-treat; PP, per protocol; BMI, bodymass index;MM
cerebrospinal fluid; Ab1–42, amyloid beta peptide 1–42; T-tau, total tau; P-tau, 18
NOTE. Data presented as mean (SD) unless otherwise stated. Percentages are c
*White matter lesions were defined as computed tomographic evidence of exte
metrical areas of low attenuation (intermediate density between normal white matte
semiovale, and at least one lacunar infarct and/or magnetic resonance imaging
confluent hyperintensities, or extensive white matter changes.
yHachinski scores were collected retrospectively after enrollment from reviewprimary end points, interaction graphics were produced
to explore the relationship between baseline CSF Ab1–42
and the change from baseline in CogState executive func-
tion/working memory. None of these interactions were
significant; further visual inspection of the interaction
graphs did not suggest that baseline Ab1–42 impacted the
level of response to rilapladib.Placebo Rilapladib
62 62
62 61
61 60
54 50
46:54 53:47
73.1 (5.40) 72.9 (5.15)
26.5 (4.83) 26.2 (3.28)
1.3 (1-14) 1.4 (1-5)
22.9 (1.98) 22.8 (2.12)
3.8 (1.66) 3.8 (1.58)
54:46 53:47
62 60
59 58
38 30
) 48 50
84 77
3 10
) 13 13
2.6 (1.78) 3.2 (2.18)
SE,Mini-Mental Status Examination; CDR, Clinical Dementia Rating; CSF,
1 phopshorylated tau.
alculated as percent of subjects in the ITT population.
nsive periventricular and deep white matter lesions: patchy or diffuse sym-
r and cerebrospinal fluid), with ill-defined margins extending to the centrum
evidence of white matter lesions: extending caps, irregular halo, diffusely
of historical medical records.
Table 2
Statistical analysis of change from baseline in CSF and plasma biomarkers at week 24/end of study (ITT population)
Biomarker* Treatment N Adjusted mean (SE)
Difference vs. placeboy,
D (95% CI)
Posterior probability
D , 0
CSF Ab1–42 (ng/L) Placebo
Rilapladib 250 mg
53
48
26.3 (18.10)
33.6 (19.02)
39.8 (212.4, 92.0)
P 5 .133z
0.934 (D . 0)
0.573 (D . 35)
0.127 (D . 70)
CSF Ab1–40 (ng/L) Placebo
Rilapladib 250 mg
53
48
277.4 (181.33)
2327.7 (190.56)
2250.3 (2772.9, 272.2) 0.829
CSF Ab1–42/CSF Ab1–40 ratio Placebo
Rilapladib 250 mg
53
48
0.002 (0.0068)
0.018 (0.0071)
0.016 (20.003, 0.036) Not calculated
AlbQ Placebo
Rilapladib 250 mg
46
40
0.11 (0.172)
20.13 (0.184)
20.24 (20.74, 0.26) 0.828
T-tau (ng/L) Placebo
Rilapladib 250 mg
52
46
38.2 (29.98)
218.8 (31.90)
257.1 (2144.5, 30.3) 0.902x
P-tau (ng/L) Placebo
Rilapladib 250 mg
52
47
1.3 (1.67)
21.7 (1.76)
23.0 (27.9, 1.8) 0.892x
NF-L (ng/L) Placebo
Rilapladib 250 mg
52
48
191.2 (215.45)
265.4 (224.38)
2256.6 (2878.6, 365.4) 0.792x
Plasma Ab1–42 (ng/L) Placebo
Rilapladib 250 mg
51
47
1.5 (0.90)
0.2 (0.94)
21.3 (23.9, 1.2) Not calculated
Plasma Ab1–40 (ng/L) Placebo
Rilapladib 250 mg
51
47
8.8 (3.91)
9.7 (4.06)
1.0 (210.2, 12.2) Not calculated
Plasma Ab1–42/Plasma Ab1–40 ratio Placebo
Rilapladib 250 mg
51
47
20.010 (0.0045)
20.012 (0.0047)
20.003 (20.016, 0.010) Not calculated
Abbreviations: CSF, cerebrospinal fluid; ITT, intent-to-treat; SE, standard error; CI, confidence interval; Ab1–42, amyloid beta peptide 1–42; Ab1–40, amyloid
beta peptide 1–40; AlbQ, albumin quotient; T-tau, total tau; P-tau, 181 phopshorylated tau, NF-L, neurofilament light chain.
*CSF parameters are using end of study samples, plasma parameters use week 24 samples.
yDifference in adjusted least square means is shown (rilapladib minus placebo).
zHypothesis testing only performed on CSF Ab1–42.
xPosterior probabilities for these end points were calculated as post hoc analysis.
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On-treatment AEs were reported by 63% of placebo sub-
jects and 64% of rilapladib subjects. Most AEs were of mild-
to-moderate intensity. Most common AEs are summarized
in Table 4. The incidence of AEs where investigators deter-
mined there was a reasonable possibility of a relationship to
study drug was 15% in each treatment group.
More rilapladib subjects reported a serious adverse event
(SAE; eight subjects [13%]) than placebo (five subjects
[8%]). No individual SAE was reported by more than one
subject. Two deaths occurred. One subject in the rilapladib
group died of a cerebral hemorrhage, 125 days after starting
drug and 8 days after their last dose. One subject in the pla-
cebo group completed the 24-week treatment period and
died of pulmonary embolism 23 days later. See
Supplementary Table 6 for further details.
More rilapladib subjects had an AE leading to withdrawal
(seven subjects [11%]) than placebo (two subjects [3%];
Table 5).
Mean changes in hematology, clinical chemistry, urinaly-
sis, vital signs, and ECG parameters were generally small
and comparable across treatment groups with no excess of
clinically significant changes on rilapladib compared to pla-
cebo. There was no evidence of phospholipidosis as evalu-
ated by eye examinations and electron microscopy of
peripheral blood lymphocytes.4. Discussion
The aim of this exploratory study was to assess whether
evidence of the findings from nonclinical studies could be
detected in a relevant AD population and to test the hypoth-
esis that rilapladib, through restoration of BBB integrity
(i.e., a reduced AlbQ), would affect downstream markers
of Abmetabolism (i.e., CSF and plasma Ab), neurodegener-
ation (i.e., tau, P-tau, and NF-L) and cognition.
The study demonstrated an improved outcome on
cognition with rilapladib. There was no biomarker evi-
dence supporting an effect of Lp-PLA2 inhibition on
Ab. The study also provided preliminary evidence of
directionally consistent, effects on AlbQ and all the
measured neurodegenerative biomarkers, although the
confidence intervals of differences between treatments en-
compassed zero. The study, therefore, provides partial
translational support for the nonclinical observations
[10]. However, given the atypical nature of the preclinical
model, the findings on cognition and neurodegenerative
markers in this present study provide a rationale for the
further evaluation of this novel mechanism.
The plasma PKs and pharmacodynamics of rilapladib
were similar to that observed in a previous clinical study
in atherosclerosis [6] with plasma Lp-PLA2 activity reduced
by approximately 80% and to a level consistent with the ef-
fects observed in the nonclinical model [1,10].
Table 3
Statistical analysis of change from baseline in cognitive data at week 24 (ITT population)
Composite score Treatment n Adjusted mean (SE)
Difference vs. placebo*,
D (95% CI) ES (95% CI)
Posterior probability
ES .0, 0.15, 0.3
Working memory/
executive functiony
Placebo
Rilapladib 250 mg
56
48
20.150 (0.0501)
0.016 (0.0538)
0.167
(0.021, 0.313)
P 5 .026z
0.446
(0.055, 0.836)
0.987 (D . 0)
0.930 (D . 0.15)
0.764 (D . 0.3)
Overall compositex Placebo
Rilapladib 250 mg
53
48
20.121 (0.0445)
0.017 (0.0466)
0.138
(0.010, 0.267)
0.428
(0.032, 0.824)
0.982 (D . 0)
0.912 (D . 0.15)
0.729 (D . 0.3)
Episodic memoryjj Placebo
Rilapladib 250 mg
53
50
20.144 (0.0989)
0.053 (0.1015)
0.197
(20.085, 0.479)
0.274
(20.119, 0.667)
0.915 (D . 0)
0.731 (D . 0.15)
0.443 (D . 0.3)
Attention{ Placebo
Rilapladib 250 mg
55
48
20.089 (0.0686)
20.019 (0.0729)
0.070
(20.130, 0.269)
0.137
(20.256, 0.530)
Not calculated
Abbreviations: ITT, intent-to-treat; SE, standard error; D, difference between treatments; CI, confidence interval; ES, effect size.
*Difference in adjusted least square means is shown (rilapladib minus placebo).
yWorking memory/executive function composite score included Controlled Oral Word Association Test, category naming, one back, Trails B, and Go/NoGo.
zHypothesis testing only performed on working memory/executive function composite score.
xOverall composite score included all nine subtests: International Shopping List Task (ISLT) immediate recall, ISLT delayed recall, Controlled Oral Word
Association Test, category naming, one back, Identification, Trails A, Trails B, and Go/NoGo.
jjEpisodic memory included ISLT immediate recall only. This change to the protocol was prespecified in the reporting and analysis plan before unblinding.
{Attention composite included Identification and Trails A.
G. Maher-Edwards et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 1 (2015) 131-140 137Two germane features of the study population are
the inclusion of subjects with a clinical diagnosis of
possible AD and the requirement for neuroimaging evi-
dence of significant CVD. Examination of baseline
CSF profiles of Ab1–42, tau, and P-tau indicated that
approximately 50% of these subjects met the assay
thresholds for AD. This may reflect the early stage of
the disease and/or an impact of cerebrovascular lesions
on the presenting dementia. Although amyloid scans
were not performed, the baseline CSF Ab1–42 profile
indicates that approximately 60% of the study popula-
tion may have been amyloid positive. Exploratory inter-
action testing, for the two primary end points, did
not suggest that baseline Ab1–42 impacts the level of
treatment response. This may indicate that the effect of
rilapladib on cognition is not dependent on the presence
of cerebral amyloidosis, although this will requireTable 4
Summary of on treatment AEs occurring in 5%* of subjects (safety
population)
Preferred term*
Placebo
(N 5 62)
Rilapladib 250 mg
(N 5 61)
Any event, n (%) 39 (63) 39 (64)
Headache 10 (16) 3 (5)
Dizziness 4 (6) 3 (5)
Nausea 5 (8) 2 (3)
Urinary tract infection 6 (10) 1 (2)
Diarrhea 2 (3) 4 (7)
Cystitis 0 4 (7)
Fatigue 3 (5) 2 (3)
Abbreviation: AE, adverse event.
*Individual adverse events presented in the table are only those preferred
terms with an incidence 5% in any treatment group.further review after larger studies in a similar dementia
population.
The neuroimaging evidence (i.e., white matter abnormal-
ities and lacunes) required for the study is typical of those
associated with SVD, as it was hypothesized that this may
have increased the potential to detect treatment effects
because of the pathologic changes associated with these le-
sions (e.g., increased BBB permeability and extravasation of
plasma components into the brain) reflecting the changes in
the nonclinical model [10]. The neuroimaging evidence
associated with the study population was largely related to
white matter changes (approximately 90%). No further in-
formation was collected regarding the nature of the cerebro-
vascular disease. Consequently, it is a recognised weakness
of the study that it is not possible to further examine the data
to understand the relationship of the underlying CVD pathol-
ogy of the dementia to any effect of rilapladib. Future studies
should seek to address these questions.
A bespoke cognitive battery targeting the domains of
executive function, working memory, attention, and
episodic memory was used to maximize the possibility
of identifying a placebo decline and a treatment response
in this small, short duration study. An EF/WM composite
was the primary comparison of interest within the cogni-
tive battery based on its relevance to the study population
[26]. By week 24, decline in cognition was evident across
the composite scores assessed for placebo but not for rila-
pladib. This effect on cognition is noteworthy as it was
achieved in addition to stable symptomatic therapy, and
it was the maximum achievable under the constraints of
the study design for a mechanism that may slow disease
progression and not anticipated to be procognitive. This
profile was supported by the absence of procognitive
effects at 12 weeks.
Table 5
Summary of SAEs and AEs leading to withdrawal (safety population)
Event
Placebo
(N 5 62)
Rilapladib
250 mg (N 5 61)
Any SAE* 5 (8) 8 (13)
Any AE leading to withdrawal, n (%) 2 (3) 7 (11)
Cerebral hemorrhage 0 1 (2)
Dementia Alzheimer’s type 0 1 (2)
Dizziness 1 (2) 0
Hypoaesthesia 1 (2) 0
Agitation 0 1 (2)
Anxiety 0 1 (2)
Confusional state 0 1 (2)
Disorientation 0 1 (2)
Nausea 1 (2) 1 (2)
Femoral neck fracture 0 1 (2)
Pain in extremity 1 (2) 0
Abbreviations: SAE, serious adverse event; AE, adverse event.
*Further details of SAEs are provided in Supplementary Table 6.
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encouraging with 80%–90% Bayesian posterior probabil-
ities that, given the observed data, at this early time point
there was a true difference between treatments. Tau and
P-tau are considered measures of neuronal damage and
neurodegeneration, and both biomarkers are increased
early in the disease and remain elevated during the course
of the disease [27]. NF-L was assessed as an exploratory
measure of white matter (axonal) damage, as it has been
reported to be increased in some forms of dementia with
subcortical involvement [28] and in demyelinating dis-
eases, such as multiple sclerosis where treatment-
related reductions in this marker have been noted [29].
The consistent directional pattern of changes in the
disease-related biomarkers in the present study is sup-
portive of the cognitive findings and suggests the poten-
tial for an underlying slowing of the progression of the
disease [27].
The underlying mechanism behind these changes is not
certain as the study provided only partial support to the
nonclinical observations in the pig model [10]. The small
decrease in AlbQ is supportive of a reduction in BBB perme-
ability but it is unclear whether the magnitude of the change
is clinically significant. Although a number of studies have
reported increases in BBB permeability in AD, vascular
forms of dementia and SVD, there are limited data on longi-
tudinal changes and their impact on disease progression
[30]. Additional supporting evidence of an effect of LpPLA2
inhibition on reducing the permeability of CNS barriers has
been provided from the investigation of the structurally
related compound darapladib (SB480848) in a phase 2a
study of diabetic macular edema patients (Clinicaltrials.
gov identifier: NCT01506895), which demonstrated
treatment-related reductions in macular edema [31].
The observed effects on CSF and plasma Ab are not
supportive of an effect of rilapladib on Ab metabolism.
This may reflect the insensitivity of the Ab-related mea-
sures used in the present study, a lack of translation fromthe nonclinical model or a more dominant role of the
cerebrovascular mechanisms on the observed treatment
responses.
Rilapladib was generally well tolerated in this study
although there were a greater number of subjects with
SAEs and a greater number of subjects who withdrew due
to AEs. One subject died in each treatment group. No
SAE was experienced by more than one subject, and there
was no obvious pattern associated with the SAEs. A num-
ber of the AEs leading to withdrawal in the rilapladib group
were psychiatric events (agitation, anxiety, confusion, and
disorientation). These events did not individually lead to
withdrawal in more than one subject in the rilapladib group,
and they were experienced as frequently by subjects in the
placebo group but did not lead to withdrawal. Given the
small size of the study and the correspondingly small num-
ber of events, it is not possible to draw wider conclusions on
these findings and this will need to be monitored in future
studies.
Although these findings are encouraging, a note of
caution is required. This is the first study to investigate
Lp-PLA2 inhibition in AD. Replication of data in AD
has been notoriously difficult in recent years particularly
for disease-modifying compounds and particularly when
moving from small, experimental phase 2 studies to
longer term clinical studies. The study was a small study
of short duration and was not intended to definitively
determine the likelihood of long-term benefit. Important
next steps to build on the findings here will be to more
fully understand the mechanism and its relationship to
different segments of the dementia population; to further
evaluate the cognitive profile over a longer time course
and across a wider range of domains; and to assess the
impact on other clinically established outcomes such as
function and quality of life.
As a whole, the findings provide initial evidence support-
ive that rilapladib and inhibition of Lp-PLA2 may have the
potential to slow the progression of AD and alter the under-
lying pathology in a subpopulation of AD patients with neu-
roimaging evidence of CVD.Acknowledgments
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1. Systematic review: Changes to the neurovascular
unit are an increasingly recognised pathologic
feature of Alzheimer’s disease, which may be linked
to changes in amyloid beta peptide (Ab) metabolism
in the brain. Findings from a nonclinical model sug-
gested that inhibition of lipoprotein phospholipase
A2 (Lp-PLA2) might provide therapeutic benefit
through effects on the blood-brain barrier (BBB)
and (Ab). An exploratory study was designed to
examine whether these nonclinical findings were
translatable using a subgroup of AD patients with
neuroimaging evidence of cerebrovascular disease
through the use of a targeted battery of mechanism
based and disease-related biomarkers and cognitive
tests.
2. Interpretation: A consistent pattern of improved
cognitive outcomes was observed across all assessed
domains, which was statistically significant on the
Executive Function/Working Memory composite
score compared to placebo. Although there was no
biomarker evidence supporting an effect of Lp-
PLA2 inhibition on any of the Ab-related
mechanism-based biomarkers, there was preliminary
evidence of directionally consistent effects on BBB
permeability (i.e., albumin quotient) and neurode-
generative biomarkers (i.e., tau, P-tau, and neuro-
filament light chain). Together these findings provide
preliminary evidence that Lp-PLA2 inhibition may
play a role in reducing BBB permeability, which may
lead to an effect on the underlying disease process. It
is uncertain at this point whether Ab plays a role in
this mechanism.
3. Future directions: Although the study provides pre-
liminary evidence that rilapladib and inhibition of
Lp-PLA2 may have the potential to slow the pro-
gression of AD, these findings require replication and
extension in longer term clinical trials to fully eval-
uate the safety and therapeutic potential of Lp-PLA2
inhibition as a treatment approach for AD.References
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